VisionPoint Advisory Group »

Brainstorm Cell Therapeutics shares owned by VisionPoint Advisory Group

Quarter-by-quarter ownership of Brainstorm Cell Therapeutics (BCLI) shares owned by VisionPoint Advisory Group from 13F filings

Historical chart of VisionPoint Advisory Group investment in Brainstorm Cell Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Brainstorm Cell Therapeutics held by VisionPoint Advisory Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Brainstorm Cell Therapeutics by VisionPoint Advisory Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $530 1.9k 0.27
2023-09-30 $388 1.9k 0.20
2023-06-30 $4.0k 1.9k 2.06

More positions owned by VisionPoint Advisory Group

Spdr Ser Tr Portfoli S&p1500 (SPTM)
Ishares Tr 1 3 Yr Treas Bd (SHY)
Spdr Ser Tr Portfolio Agrgte (SPAB)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
Ishares Tr Mortge Rel Etf (REM)
First Tr Nasdaq 100 Tech Ind SHS (QTEC)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
Deere & Company (DE)
Philip Morris International (PM)
Spdr Gold Tr Gold Shs (GLD)
JPMorgan Chase & Co. (JPM)
Microsoft Corporation (MSFT)
Agnc Invt Corp Com reit (AGNC)
Spdr Ser Tr Bloomberg 1-3 Mo (BIL)
Spdr Ser Tr Portfolio Short (SPSB)

View all positions for VisionPoint Advisory Group

Top funds holding Brainstorm Cell Therapeutics

Vanguard Group
Liberty Wealth Management
Weaver Consulting Group
Caldwell Sutter Capital
Abner, Herrman & BrocK
Raymond James & Associates
ADAR1 Capital Management
Ikarian Capital
Kingswood Wealth Advisors
Citadel Advisors
Virtu Financial
Jmac Enterprises
Barclays
Wells Fargo & Company
Saxony Capital Management

View all funds holding Brainstorm Cell Therapeutics